Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer

Oncology Reports

Volumn 31, Issue 3, 2014, Pages 1051-1058

  Sawada, Yu ^a,b   Komori, Hiroyuki ^c   Tsunoda, Yoshiyuki ^a,d   Shimomura, Manami ^a   Takahashi, Mari ^a   Baba, Hideo ^c   Ito, Masaaki ^a   Saito, Norio ^a   Kuwano, Hiroyuki ^d   Endo, Itaru ^b   Nishimura, Yasuharu ^c   Nakatsura, Tetsuya ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d GUNMA UNIVERSITY   (Japan)

Author keywords

Cancer immunotherapy; Colorectal cancer; Cytotoxic T cell; Heat shock protein 105; HLA transgenic mice

Indexed keywords

EPITOPE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 105 VACCINE; HLA A2 ANTIGEN; HLA A24 ANTIGEN; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG TARGETING; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN TARGETING;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A2 ANTIGEN; HLA-A24 ANTIGEN; HSP110 HEAT-SHOCK PROTEINS; HUMANS; IMMUNIZATION; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84896736403     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2941     Document Type: Article

References (28)

1. Weitz J, Koch M, Debus J, Höhler T, Galle PR and Büchler MW: Colorectal cancer. Lancet 365: 153-165, 2005. (Pubitemid 40091806)
2. Mlecnik B, Tosolini M, Kirilovsky A, et al: Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29: 610-618, 2011.
3. Nakatsura T, Senju S, Yamada K, Jotsuka T, Ogawa M and Nishimura Y: Gene cloning of immunogenic antigens overexpressed in pancreatic cancer. Biochem Biophys Res Commun 281: 936-944, 2001. (Pubitemid 32917821)
4. Kai M, Nakatsura T, Egami H, Senju S, Nishimura Y and Ogawa M: Heat shock protein 105 is overexpressed in a variety of human tumors. Oncol Rep 10: 1777-1782, 2003.
5. Hatayama T, Yasuda K and Nishiyama E: Characterization of high-molecular-mass heat shock proteins and 42 degrees C-specific heat shock proteins of murine cells. Biochem Biophys Res Commun 204: 357-365, 1994. (Pubitemid 24335303)
6. Miyazaki M, Nakatsura T, Yokomine K, Senju S, Monji M, Hosaka S, et al: DNA vaccination of HSP105 leads to tumor rejection of colorectal cancer and melanoma in mice through activation of both CD4 T-cells and CD8 T-cells. Cancer Sci 96: 695-705, 2005. (Pubitemid 41723547)
7. Yokomine K, Nakatsura T, Minohara M, et al: Immunization with heat shock protein 105-pulsed dendritic cells leads to tumor rejection in mice. Biochem Biophys Res Commun 343: 269-278, 2006.
8. Yokomine K, Nakatsura T, Senju S, Nakagata N and Minohara M: Regression of intestinal adenomas by vaccination with heat shock protein 105-pulsed bone marrow-derived dendritic cells in Apc(Min/+) mice. Cancer Sci 98: 1930-1935, 2007. (Pubitemid 350002199)
9. Browning M and Krausa P: Genetic diversity of HLA-A2: evolutionary and functional significance. Immunol Today 17: 165-170, 1996. (Pubitemid 26113084)
10. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA and Pérarnau B: HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185: 2043-2051, 1997. (Pubitemid 27265987)
11. Firat H, Garcia-Pons F, Tourdot S, et al: H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol 29: 3112-3121, 1999. (Pubitemid 29484201)
12. Hosaka S, Nakatsura T, Tsukamoto H, Hatayama T, Baba H and Nishimura Y: Synthetic small interfering RNA targeting heat shock protein 105 induces apoptosis of various cancer cells both in vitro and in vivo. Cancer Sci 97: 623-632, 2006. (Pubitemid 44056611)
13. Komori H, Nakatsura T, Senju S, et al: Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 12: 2689-2697, 2006.
14. Nakatsura T, Komori H, Kubo T, et al: Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 10: 8630-8640, 2004. (Pubitemid 40053431)
15. Nakatsura T, Senju S, Ito M, Nishimura Y and Itoh K: Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 32: 826-836, 2002. (Pubitemid 34257560)
16. Yoshitake Y, Nakatsura T, Monji M, et al : Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res 10: 6437-6448, 2004. (Pubitemid 39346538)
17. Monji M, Nakatsura T, Senju S, et al: Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin Cancer Res 10: 6047-6057, 2004. (Pubitemid 39287509)
18. Feder ME and Hofmann GE: Heat-shock proteins, molecular chaperones and the stress response: evolutionary and ecological physiology. Annu Rev Physiol 61: 243-282, 1999. (Pubitemid 29143171)
19. Craig EA, Weissman JS and Horwich AL: Heat shock proteins and molecular chaperones: mediators of protein conformation and turnover in the cell. Cell 78: 365-372, 1994. (Pubitemid 24250802)
20. Hwang TS, Han HS, Choi HK, et al: Differential, stage-dependent expression of Hsp70, Hsp110 and Bcl-2 in colorectal cancer. J Gastroenterol Hepatol 18: 690-700, 2003. (Pubitemid 36791708)
21. Kawakami Y and Rosenberg SA: Human tumor antigens recognized by T-cells. Immunol Res 16: 313-339, 1997. (Pubitemid 28026418)
22. van der Bruggen P, Traversari C, Chomez P, et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991. (Pubitemid 21917508)
23. Kawakami Y, Eliyahu S, Delgado CH, et al: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91: 6458-6462, 1994.
24. Srivastava P: Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20: 395-425, 2002.
25. Hickman-Miller HD and Hildebrand WH: The immune response under stress: the role of HSP-derived peptides. Trends Immunol 25: 427-433, 2004. (Pubitemid 38951084)
26. Romero P, Cerottini JC and Speiser DE: Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother 53: 249-255, 2004. (Pubitemid 38328048)
27. Jäger E, Chen YT, Drijfhout JW, et al: Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187: 265-270, 1998. (Pubitemid 28060443)
28. + T-cell to a fully functional tumor killer cell. Cancer Res 62: 6438-6441, 2002.